Pooled meta-analysis studies of MDS patients have shown that patients with SRSF2 mutations predict for a worse survival and an increased risk for AML transformation [32,33] and have no prognostic effects in CMML [34]. This evidence concerns the gene SRSF2 and acute myeloid leukemia.